Bhagwat, N., Liu, D., Wu, X., Grego, A., Crossan, A., Moore, A., Mondal, A., Bachner, C., Elrio, D., Roth, D., Rose, J., Rager, J., Cote, J., Gallagher, K., Bersch, K., Cowart, M., Kurtz, N., DiBiaso, A., Sumerau, M., Osinubi, O., Wang, M., Chandratre, S., Mei, S., Dhar, S., Rodgers, S., Ratna, S., Loret, Y., Zou, Y., Geeganage, S., Combs, A., Kiladjian, J., Giraudier, S., Scherle, P. (2025). Discovery and preclinical characterization of orally bioavailable JAK2V617F mutant selective JH2 inhibitors with disease modification potential in myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood-2025-70